CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于溶瘤病毒的 DC 疫苗在癌症中的方法：迈向针对胶质母细胞瘤（GBM）患者的多阶段联合治疗策略
英文原题：Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.
查看英文原题
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）仍是一种预后不良的孤儿癌症疾病。需要新的治疗策略。免疫治疗有多种作用方式。加入树突状细胞疫苗的主动特异性免疫治疗可改善患者的总生存期。将DC疫苗接种整合到一线联合治疗中成为一项挑战，化疗期间的免疫原性细胞死亡免疫治疗被引入。我们使用真实世界数据进行回顾性分析，以评估复杂的联合治疗，该治疗包括在标准治疗期间和之后进行的个体化多模式免疫治疗，并且需要在治疗期间进行调整，结果发现总生存期进一步改善。我们还讨论了使用真实世界数据作为证据。综述了推动GBM患者个体化多模式免疫治疗领域向前发展的新策略。
展开英文摘要原文
Glioblastoma (GBM) remains an orphan cancer disease with poor outcome. Novel treatment strategies are needed. Immunotherapy has several modes of action. The addition of active specific immunotherapy with dendritic cell vaccines resulted in improved overall survival of patients. Integration of DC vaccination within the first-line combined treatment became a challenge, and immunogenic cell death immunotherapy during chemotherapy was introduced.
We used a retrospective analysis using real world data to evaluate the complex combined treatment, which included individualized multimodal immunotherapy during and after standard of care, and which required adaptations during treatment, and found a further improvement of overall survival.
We also discuss the use of real world data as evidence. Novel strategies to move the field of individualized multimodal immunotherapy forward for GBM patients are reviewed.
论文信息
- 作者
- Van Gool SW、Van de Vliet P、Kampers LFC、Kosmal J、Sprenger T、Reich E、Schirrmacher V、Stuecker W
- 单位
- Immun-onkologisches Zentrum Köln, Cologne, Germany. Electronic address: vangool@iozk.de.Germany
- 期刊
- Methods in cell biology2024
- 原文标识
- PubMed 38548421 · DOI 10.1016/bs.mcb.2023.06.001